Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid

Status Available

Clinical Trial Summary

The objective of the program is to provide patients with Bullous Pemphigoid (BP), that participated in the R668-BP-1902 (NCT04206553) phase 2/3 study, dupilumab treatment and evaluate the long-term safety of dupilumab.

Clinical Trial Description

Expanded Access requests are only being considered in response to intermediate size patient population applications. Availability will depend on location. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05906706
Study type	Expanded Access
Source	Regeneron Pharmaceuticals
Contact	Requests for compassionate use must be initiated by a treating p
Phone	844-734-6643
Email	CompassionateUse_Requests@regeneron.com
Status	Available
Phase

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03286582` - A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid	Phase 2
Completed	`NCT02837965` - Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid
Recruiting	`NCT03636763` - Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?
Recruiting	`NCT00802243` - Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid	Phase 2
Completed	`NCT05649579` - Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid
Active, not recruiting	`NCT04206553` - A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid	Phase 2/Phase 3
Completed	`NCT00431119` - Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid	Phase 2
Completed	`NCT04563923` - Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody	Phase 2
Completed	`NCT03320798` - Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients	N/A
Completed	`NCT03272958` - Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid
Completed	`NCT02883894` - Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid	N/A
Completed	`NCT00809822` - Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.	Phase 2
Recruiting	`NCT05594472` - Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid	Phase 3
Withdrawn	`NCT05061771` - Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)	Phase 3
Not yet recruiting	`NCT04128176` - Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid	Phase 3
Recruiting	`NCT05284929` - Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
Terminated	`NCT04612790` - A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.	Phase 3
Recruiting	`NCT05681481` - A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid	Phase 3
Completed	`NCT00286325` - Rituximab in the Treatment of Patients With Bullous Pemphigoid	Phase 1/Phase 2
Completed	`NCT04728854` - Telederm and Bullous Pemphigoid